與我們的專家分析師一起探索CRISPR Therapeutics（NASDAQ：CRSP）的激動人心的世界

查看下面的視頻，以獲得對市場趨勢和潛在投資機會的寶貴見解！*使用的股票價格是2025年1月29日的價格。

In this Motley Fool Scoreboard episode, we'll be delving into the exciting world of CRISPR Therapeutics (NASDAQ:CRSP) with our expert analysts. Join them as they discuss the latest market trends and highlight potential investment opportunities.

在這個Motley愚人記分板情節中，我們將與我們的專家分析師一起研究CRISPR Therapeutics（NASDAQ：CRSP）的激動人心的世界。加入他們討論最新市場趨勢並突出潛在的投資機會時。

But first, let's see what one analyst is recommending for investing $1,000 right now.

但是首先，讓我們看看一位分析師現在建議投資1,000美元的建議。

Where to invest $1,000 right now?

現在在哪裡投資1,000美元？

Our analyst team just revealed what they believe are the 10 best stocks to buy right now.

我們的分析師團隊剛剛透露了他們認為現在要購買的10種最佳股票。

See the full ranking now.

立即查看完整的排名。

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now … and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Motley Fool Stock Advisor分析師團隊剛剛確定了他們認為現在可以購買投資者的10個最佳股票……而CRISPR Therapeutics並不是其中之一。裁員的10個股票可能會在未來幾年產生怪物回報。

Consider when Nvidia made this list on April 15, 2005 … if you invested $1,000 at the time of our recommendation, you'd have $736,343!

考慮一下NVIDIA在2005年4月15日列出此列表時……如果您在建議時投資了1,000美元，您將有736,343美元！

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002. Don't miss out on the latest top 10 list, available when you join Stock Advisor.

Stock Advisor為投資者提供了易於遵循的成功藍圖，包括有關建立投資組合的指南，分析師的定期更新以及每月兩個新的股票選秀權。自2002年以來，股票顧問服務已經超過了標準普爾500指數的回報。當您加入股票顧問時，請不要錯過最新的前10名列表。

Get started investing with our analyst team today.

立即開始與我們的分析團隊進行投資。

Now, let's get started with CRISPR Therapeutics.

現在，讓我們開始從CRISPR Therapeutics開始。

One analyst is recommending investors buy CRISPR Therapeutics stock. Despite a recent surge of over 100% in 2024, the biotech's stock price is still down 70% from its all-time high reached in November 2021.

一位分析師建議投資者購買CRISPR Therapeutics股票。儘管最近在2024年增長了100％以上，但生物技術的股票價格仍比2021年11月的歷史最高水平下降了70％。

After a strong fourth-quarter earnings report in February, enthusiasm for CRISPR has soared. The company exceeded analysts' expectations for both earnings and revenue, and it also raised its outlook for the full year.

在2月份獲得了第四季度的大量收益報告之後，對CRISPR的熱情激增。該公司超出了分析師對收入和收入的期望，並且還提高了整整一年的前景。

CRISPR is a leading developer of next-generation gene therapies, using the CRISPR-Cas9 technology to treat serious illnesses. The company's main focus is on treating blood disorders such as beta-thalassemia and sickle cell disease. Its flagship product, an experimental treatment for beta-thalassemia called bentradicimab, is currently in Phase 3 testing.

CRISPR是下一代基因療法的主要開發商，使用CRISPR-CAS9技術治療嚴重疾病。該公司的主要重點是治療血液疾病，例如β-綜合性貧血和鐮狀細胞疾病。它的旗艦產品是一種用於Bentradicimab的β-地中海貧血的實驗治療方法，目前正在第三階段測試中。

Earlier this month, CRISPR announced that it had achieved promising results in a mid-stage clinical trial of bentradicimab in treating sickle cell disease. The company observed a complete response rate of 50% in patients with beta-thalassemia who had received at least 12 months of treatment with bentradicimab.

本月初，CRISPR宣布，它在Bentradicimab的中期臨床試驗中取得了有希望的結果，以治療鐮狀細胞疾病。該公司觀察到β-甲性甲性疾病患者的完全緩解率為50％，他們接受了至少12個月的Bentradicimab治療。

In the third quarter, CRISPR posted a net loss of $108.7 million, compared to analysts' estimate of $117.5 million. The company reported earnings per share of $0.40, whereas analysts expected $0.37. Revenue for the period amounted to $140.9 million, exceeding analysts' projections of $133 million.

在第三季度，CRISPR的淨虧損為1.087億美元，而分析師的估計為1.175億美元。該公司報告的每股收益為0.40美元，而分析師預計0.37美元。該期間的收入為1.409億美元，超過了分析師的預測1.33億美元。

For the full year, CRISPR now anticipates a net loss in the range of $360 million to $390 million, narrower than the prior outlook of $400 million to $430 million. Analysts had estimated a net loss of $372 million. The biotech also raised its revenue forecast for the year to a band of $540 million to $570 million, up from the previous projection of $490 million to $520 million. Analysts had estimated revenue of $541 million.

在整整一年中，CRISPR現在預計淨虧損在3.6億至3.9億美元之間，比先前的4億至4.3億美元的前景窄。分析師估計淨虧損為3.72億美元。該生物技術還將當年的收入預測提高到了5.4億美元的樂隊，從上一年的預測4.9億美元提高到5.7億美元。分析師估計收入為5.41億美元。

Despite the promising results and optimistic outlook, one analyst remains cautious on CRISPR stock. Here's why.

儘管有令人鼓舞的結果和樂觀的前景，但一位分析師仍然對CRISPR股票保持謹慎。這就是原因。

Now playing video

現在播放視頻

portion

部分

Hello, and welcome to this edition of Motley Fool Top Buys. I'm Karl Thiel, and I'll be joined by one of The Motley Fool's expert analysts as we take a closer look at one stock that could be a promising addition to your portfolio.

您好，歡迎使用此版本的Motley傻瓜購買。我是卡爾·泰爾（Karl Thiel），我將加入Motley Fool的一位專家分析師之一，因為我們仔細研究了一張股票，這可能是您投資組合的一個有希望的補充。

We'll also be highlighting the ten best stocks to buy right now, according to The Motley Fool's analyst team. But first, let's delve into the world of CRISPR Therapeutics (NASDAQ:CRSP) with Keith Speights.

據Motley Fool的分析團隊稱，我們還將重點介紹現在購買的十個最佳股票。但是首先，讓我們與基思·斯佩斯（Keith Speights）一起研究CRISPR Therapeutics（NASDAQ：CRSP）的世界。

Now, CRISPR has been a hot stock in 2024, surging more than 100%. However, it's still down 70% from its all-time high, which it reached in November 2021.

現在，CRISPR在2024年一直是熱門股票，飆升超過100％。但是，它的歷史最高水平仍然下降了70％，它於2021年11月達到。

After a strong fourth-quarter earnings report in February, enthusiasm for CRISPR has reached new heights. The biotech beat expectations for both earnings and revenue, and it also raised its outlook for the full year.

在2月份獲得了第四季度的大量收益報告之後，對CRISPR的熱情已經達到了新的高度。 Biotech擊敗了對收入和收入的期望，並且還提高了整整一年的前景。

CRISPR is a leading developer of next-generation gene therapies, using the CRISPR-Cas9 technology to treat serious illnesses. The company's main focus is on treating blood disorders such as beta-

CRISPR是下一代基因療法的主要開發商，使用CRISPR-CAS9技術治療嚴重疾病。該公司的主要重點是治療血液疾病，例如β-